Mechanistic-Based Treatment for Common Neuropathic Pain and the Treatment Dilemma of the Elderly
DOI:
https://doi.org/10.12974/2309-6179.2013.01.01.1Keywords:
Neuropathic pain, mechanism-based, treatment dilemma, elderly.Abstract
Neuropathic pain is a complicated disorder. This complexity arises not because the characteristics of the pain differ from nociceptive inflammatory symptoms, but because of its complex mechanism. Peripheral transduction, ectopic impulse, central sensitization, low threshold A-beta fiber mediated pain, and loss of inhibitory control all play a role in the mechanism. Nevertheless, the outcomes are still unsatisfactory for physicians and patients with regards to treatment. For example, certain disorders such as central post-stroke pain are extremely difficult to treat, not only because of the intolerable side effects of the medications but also because of the unknown effectiveness of pain reduction, especially in the elderly. Under-treatment frequently occurs in the absence of attention to the pain characteristics, and because physicians are concerned of adverse effects or inappropriate up-titration of neuropathic drugs such as anti-epileptic medicines. Multidisciplinary approaches including non-pharmacological management, rehabilitation, biofeedback, acupuncture, education on stepwise pain reduction, and keeping a diary are somewhat helpful in clinical practice but not easily implemented without the cooperation of multidisciplinary teams. Physicians prescribe opioids to alleviate the symptoms, however this carries the risk of addiction. Therefore, it is important that clinicians are made aware of common neuropathic disorders in order to establish strategies to manage such types of pain.
References
Craig KD, Hadjistavropoulos T. Psychological perspectives on pain: Controversies. In Hadjistavropoulos T, Craig KD, Eds. Pain: Psychological perspectives. New York: Erlbaum. 2004; pp. 303-26.
Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008; 70: 1630-35. http://dx.doi.org/10.1212/01.wnl.0000282763.29778.59
Bennett GJ. Neuropathic pain: an overview. In: Borsook D, Ed. Molecular neurobiology of pain. Seattle, WA: IASP Press 1997; pp. 109-13.
Dieleman JP, Kerklaan J, Huygen FJPM, et al. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008; 137: 681-88. http://dx.doi.org/10.1016/j.pain.2008.03.002
(a) Smith BH, Torrance N. Epidemiology of neuropathic pain. Pain Management 2011; 1(1): 87-96. http://dx.doi.org/10.2217/pmt.10.5 (b) Gillian CH, Steve VM, Dawn C, Zahava LG, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013; 14: 28-35. http://dx.doi.org/10.1186/1471-2296-14-28
Gregorian RS, Gasik A, Kwong WJ, Voeller S, Kavanagh S. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians???? J Pain 2010; 11: 1095- 108. http://dx.doi.org/10.1016/j.jpain.2010.02.007
Leung L. From ladder to platform: a new concept for pain management. J Prim Health Care 2012; 4(3): 254-258.
Baron R. Mechanism of Disease: neuropathic pain-a clinical perspective. Nat Clin Pract Neurol 2006; 2: 95-106. http://dx.doi.org/10.1038/ncpneuro0113
Finnerup N., Troels JS. Mechanisms of Disease: mechanismbased classification of neuropathic pain-a critical analysis. Nature Clinical Practice 2006; 2: 107-15. http://dx.doi.org/10.1038/ncpneuro0118
Freynhagen R, Bennett MI. Diagnosis and management of neuropathic pain. BMJ 2009; 339: b3002. http://dx.doi.org/10.1136/bmj.b3002
Dworkin RH, O’Connor AB, Backonja M. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132: 237-51. http://dx.doi.org/10.1016/j.pain.2007.08.033
Cummins TR, Dib-Hajj SD, Black JA, et al. Sodium channels and the molecular pathophysiology of pain. Prog Brain Res 2000; 129: 3-19. http://dx.doi.org/10.1016/S0079-6123(00)29002-X
Britton NF, Chaplain MA, Skevtnftonj SM, et al. The role of Nmethyl- D-aspartate (NMDA) receptors in wind-up: A mathematical model. IMA Journal of Mathematics Applied in Medicine & Biology 1996; 13: 193-205. http://dx.doi.org/10.1093/imammb/13.3.193
Petrenko AB, Yamakura T, Hiroshi B, et al. The Role of NMethyl- D-Aspartate (NMDA) Receptors in Pain: A Review. Anesth Analg 2003; 97: 1108-16. http://dx.doi.org/10.1213/01.ANE.0000081061.12235.55
Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000; 19: S21-S25. http://dx.doi.org/10.1016/S0885-3924(99)00125-6
Dumont RJ, Okonkwo DO, Verma S, et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001; 24: 254-64. http://dx.doi.org/10.1097/00002826-200109000-00002
Wasner G, Lee BB, Engel S, et al. Residual spinothalamic tract pathways predict development of central pain after spinal cord injury. Brain 2008; 131: 2387-400. http://dx.doi.org/10.1093/brain/awn169
Hughes DI, Scott DT, Todd AJ, Riddell JS. Lack of evidence for sprouting of Abeta afferents into the superficial laminas of the spinal cord dorsal horn after nerve section. J Neurosci 2003; 23: 9491-9.
Marks DM, Shah MJ, Patkar AA, et al. Serotonin- Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise. Current Neuropharmacology 2009; 7: 331-6. http://dx.doi.org/10.2174/157015909790031201
Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10(9): 732-47.
Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004; 110: 461-69. http://dx.doi.org/10.1016/j.pain.2004.04.034
Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007; 127: 199-203. http://dx.doi.org/10.1016/j.pain.2006.10.034
Haanpaa ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009; 122: S13-21. http://dx.doi.org/10.1016/j.amjmed.2009.04.006
Taiwan Guidance for Total Pain Management.
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanism and treatment. Lancet Neurology 2010; 9: 807-19. http://dx.doi.org/10.1016/S1474-4422(10)70143-5
Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the non-pharmacologic management of migraine in clinical practice. Canadian Headache Society. CMAJ 1998; 159(1): 47-54.
Tfelt-Hansen PC, Koehler PJ. One Hundred Years of Migraine Research: Major Clinical and Scientific Observations From 1910-2010. Headache 2011; 51: 752????-78.
Gilron I, Peter C, Watson N, et al. Neuropathic Pain: a practical guide for the clinician. CMAJ 2006; 175(3); 265-75. http://dx.doi.org/10.1503/cmaj.060146
Norrbrink BC, Kowalski J, Lundeberg T. et al. A comprehensive pain management program comprising educational, cognitive and behavioural interventions for neuropathic pain following spinal cord injury. J Rehabil Med 2006; 38(3): 172-80. http://dx.doi.org/10.1080/16501970500476258
Guastella V, Mick G, Laurent B. Non pharmacologic treatment of neuropathic pain. Presse Med 2008; 37: 354???? http://dx.doi.org/10.1016/j.lpm.2007.11.008
Linde K, Allais G, Brinkhaus B, Manheimer E, Vickers A, White AR. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009; 21(1): CD 0012018.
Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965; 150: 971-9. http://dx.doi.org/10.1126/science.150.3699.971
Melzack R. Gate control theory: On the evolution of pain concepts. Pain Forum 1996; 5(1): 128-38.
Austin JH. Zen and the Brain. MIT Press, Cambridge, Mass and London, England 1998.
Dworkin RH, O’Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007; 132: 237-51. http://dx.doi.org/10.1016/j.pain.2007.08.033
Cruccu G, Sommera C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. European Journal of Neurology 2010; 17: 1010-18. http://dx.doi.org/10.1111/j.1468-1331.2010.02969.x
Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update Mayo Clin Proc 2010; 85(3): S3-14. http://dx.doi.org/10.4065/mcp.2009.0649
Tan T, Barry P, Reken S, et al. Pharmacological management of neuropathic pain in adults in non-specialist settings: summary of NICE guidance. BMJ 2010; 340: c1079. http://dx.doi.org/10.1136/bmj.c1079
Attal N, Cruccua G, Barona R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010; 17: 1113-23. http://dx.doi.org/10.1111/j.1468-1331.2010.02999.x
Hong Kong Pain Society Limited. Handbook of Neuropathic Pain Management Guidelines, 2nd ed. 2011; 1-33.
National Institute for Health and Clinical Excellence (NICE). Clinical Guideline 96: Neuropathic pain- The pharmacological management of neuropathic pain in adults in non-specialists setting. 2010; 1-25.
Haanpaa M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011; 152(1): 14-27. http://dx.doi.org/10.1016/j.pain.2010.07.031
Helgason S, Petursson G, Gudmundsson S, et al. A Prevalence of postherpetic neuralgia after a single episode of herpes zoster: prospective study with long-term follow up. BMJ 2000; 321: 1-4. http://dx.doi.org/10.1136/bmj.321.7264.794
(a) Delaney A, Colvin LA, Fallon MT, et al. Postherpetic neuralgia: from preclinical models to the clinic. Neurotherapeutics 2009; 6(4): 630-7. http://dx.doi.org/10.1016/j.nurt.2009.07.005 (b) Jih JS, Chen YJ, Lin MW, Chen YC, Chen TZ, Huang YL, et al. Epidemiological Features and Costs of Herpes Zoster in Taiwan: A National Study 2000 to 2006. Acta Derm Venereol 2009; 89: 612-616. http://dx.doi.org/10.2340/00015555-0729
Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010; 26(7): 1607-19. http://dx.doi.org/10.1185/03007995.2010.483675
Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011; 107(4): 490-502. http://dx.doi.org/10.1093/bja/aer260
Backonia M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008; 7(12): 1106-12. http://dx.doi.org/10.1016/S1474-4422(08)70228-X
Hsu W-C, Chiu Y-H, Chiu H-C, et al. Two-Stage Community- Based Screening Model for Estimating Prevalence of Diabetic Polyneuropathy. Neuroepidemiology 2005; 25: 1-7. http://dx.doi.org/10.1159/000085306
Boulton AJ, Vinik AI, Arezzo JC, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-62. http://dx.doi.org/10.2337/diacare.28.4.956
Tesfaye S, Chaturvedi N, Eaton SE, et al. EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-50. http://dx.doi.org/10.1056/NEJMoa032782
Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76: 1758-65. http://dx.doi.org/10.1212/WNL.0b013e3182166ebe
IASP. Neuropathic Pain. Core Curriculum for Professional Education in Pain, edited by J. Edmond Charlton, IASP Press, Seattle, 2005.
Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71(15): 1183-90. http://dx.doi.org/10.1212/01.wnl.0000326598.83183.04
Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalagia 2011; 31(15): 1542-8. http://dx.doi.org/10.1177/0333102411424619
International Headache Society. The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 2004; 24(Suppl 1): 1-160.
Cruccu G, Biasiotta A, Galeotti F, et al. Diagnostic accuracy of trigeminal reflex testing in trigeminal neuralgia. Neurology 2006; 66 (1): 139-41. http://dx.doi.org/10.1212/01.wnl.0000191388.64530.8f
Chen P, LinM JJ, Lu CS, et al. Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan. N Engl J Med 2011; 364: 1126-33. http://dx.doi.org/10.1056/NEJMoa1009717
Kim JH, Greenspan JD, Coghill RC, et al. Lesions Limited to the Human Thalamic Principal Somatosensory Nucleus (Ventral Caudal) Are Associated with Loss of Cold Sensations and Central Pain. The Journal of Neuroscience 2007; 27(18): 4995-5005. http://dx.doi.org/10.1523/JNEUROSCI.0716-07.2007
Gustin SM, Peck CC Wilcox SL, et al. Different Pain, Different Brain: Thalami Anatomy in Neuropathic and Non- Neuropathic Chronic Pain Syndromes The Journal of Neuroscience 2011; 31(16): 5956 -64. http://dx.doi.org/10.1523/JNEUROSCI.5980-10.2011
Vanegas H, Schaible HG. Descending control of persistent pain: inhibitory or facilitatory? Brain Res Rev 2004; 46: 295- 309. http://dx.doi.org/10.1016/j.brainresrev.2004.07.004
Lenz FA, Lee JI, Garonzik IM, et al. Plasticity of pain-related neuronal activity in the human thalamus. Prog Brain Res 2000; 129: 259-73. http://dx.doi.org/10.1016/S0079-6123(00)29019-5
Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184-90. http://dx.doi.org/10.1212/WNL.56.2.184
Fontaine D, Hamani C, Lozano A. E????cacy and safety of motor cortex stimulation for chronic neuropathic pain: critical review of the literature. J Neurosurg 2009; 110: 251-56. http://dx.doi.org/10.3171/2008.6.17602
Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology, and management. Lancet Neurol 2009; 8: 857-68. http://dx.doi.org/10.1016/S1474-4422(09)70176-0
Gyanendra K, Chetan RS. Central post-stroke pain: Current Journal of the Neurological Sciences 2009; 284: 10-17. http://dx.doi.org/10.1016/j.jns.2009.04.030
Frese A, Husstedt IW, Ringelstein B, et al. Pharmacologic Treatment of Central Post-Stroke Pain. Clin J Pain 2006; 22: 252-60. http://dx.doi.org/10.1097/01.ajp.0000173020.10483.13
Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006; 67: 1792-800. http://dx.doi.org/10.1212/01.wnl.0000244422.45278.ff
Finnerup NB, Jensen TS. Clinical use of pregabalin in the management of central neuropathic pain. Neuropsychiatric Disease and Treatment 2007; 3(6): 885-91. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8.
Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8. http://dx.doi.org/10.1016/s0304-3959(03)00006-x
Berger A, Dukes EM, Edelsberg J, Stacey BR, Oster G. Use of tricyclic antidepressants in older patients with painful neuropathies. Eur J Clin Pharmacol 2006; 62(9): 757-64. http://dx.doi.org/10.1007/s00228-006-0161-8
Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45(3): 203-33. http://dx.doi.org/10.1080/15563650701226192
Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105: 133-41. http://dx.doi.org/10.1016/S0304-3959(03)00173-8 ???????????????? Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007; 73: 137-50.???? http://dx.doi.org/10.1016/j.eplepsyres.2006.09.008
Gilron I, Bailey JM, Tu D, Holden RR, Jackson AC, Houlden RL. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009; 10: 374(9697): 1252-61.
Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012; 11(7): CD008943.
Cummins TR, Dib-Hajj SD, Black JA, et al. Sodium channels and the molecular pathophysiology of pain. Prog Brain Res 2000; 129: 3-19. http://dx.doi.org/10.1016/S0079-6123(00)29002-X
Arnstein P. Chronic neuropathic pain: issues in patient education. Pain Manag Nurs 2004; 5(suppl 1): 34-41. http://dx.doi.org/10.1016/j.pmn.2004.10.003
Haslam C, Nurmikko T. Pharmacological treatment of neuropathic pain in older persons. Clinical Interventions in Aging 2008: 3(1) 111-20.
Schmader KE, Baron R, Haanpää ML, Mayer J, O’Connor AB, Rice AS, et al. Treatment Considerations for Elderly and Frail Patients With Neuropathic Pain. Mayo Clin Proc 2010; 85(3)(Suppl): S26-32.
Arnstein P. Balancing Analgesic Efi cacy with Safety Concerns in the Older Patient. Pain Manag Nurs 2010; 11(Suppl): S11-22.
Unruh AM. Spirituality, religion, and pain. Can J Nurs Res 2007; 39(2): 66-86.